Corporate Profile

Enalare Therapeutics Inc. is a privately owned clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from acute respiratory conditions.

Press Releases

September 27th, 2022
The award, stage-gated based on achievement of pre-determined milestones and deliverables, provides funding for Enalare to perform pre-clinical toxicology, human clinical studies, drug and device manufacturing, and regulatory file submission for a formulation of ENA-001 suitable for community use.
August 9th, 2022
As part of the transaction, Eagle will invest up to approximately $55 million, which is expected to occur over the next two years subject to the achievement by Enalare of certain milestones on an agreed upon timeline.
July 1st, 2022
Funding from the NIH’s National Institute on Drug Abuse (NIDA) will Support Further Development of ENA001, an Agnostic Respiratory Stimulant
June 8th, 2022
ENA001, an Agnostic Respiratory Stimulant, Successfully Achieved the Study Primary Endpoint and Was Shown to Be Safe and Well Tolerated
January 7th, 2022
This project has been funded in whole or in part with federal funds from the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority.
December 14th, 2021
Subject to FDA approval of ENA-001 for the treatment of Apnea of Prematurity, Enalare would be eligible to receive a priority review voucher that may be applied either to a subsequent product’s marketing application or sold/transferred to another company.
November 30th, 2021
This Provisional Patent Application was filed with the United States Patent and Trademark Office for its lead product ENA-001 and related compounds for the reversal of respiratory depression from non-opioid central nervous system depressants, including common surgical anesthetics. Any resultant patent claiming priority to this filing will have an estimated term to 2042.
November 4th, 2021
This study aims to demonstrate the ability of ENA-001 to reverse respiratory depression induced through administration of propofol, a central nervous system depressant commonly utilized globally as a surgical anesthetic.
November 2nd, 2021
Daniel Motto, Enalare’s Chief Operating Officer, will highlight how the successful partnership with BARDA is accelerating the development of Enalare’s lead drug candidate ENA-001 as a potential treatment for respiratory depression in both mass casualty situations and the drug overdose epidemic.
August 4th, 2021
Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening critical care conditions, announced today that it has expanded its scientific team with the appointment of Thomas Miller, Ph.D., as Vice President of Clinical Development.
April 27th, 2021
Enalare Therapeutics Inc. has received an initial contract from the Biomedical Advanced Research and Development Authority (BARDA) to support development of ENA-001.
February 2nd, 2021
The Company Raises $10 Million to Expand Its Operations and Prepare to Conduct Pivotal Studies of Lead Drug Candidate ENA-001.
January 19th, 2021
The Addition of Dr. Coleman Further Enhances the Company’s Deep Medical, Enterprise Leadership, and Capital Markets Experience.
January 12th, 2021
The Appointments of Professors Albert Dahan MD, PhD and Tong Joo (TJ) Gan MD, MHS, MBA Highlight a World Class Collection of Medical and Pharmaceutical Industry Experts.
November 17th, 2020
The addition of Gino Santini, Bob Yedid, and Joe Petko Significantly Expands Company’s Pharmaceutical and Financial Markets Experience and Capabilities.
November 9th, 2020
Enalare Therapeutics Inc. announced today that it has appointed pharmaceutical industry veteran Daniel Motto as its Chief Business Officer.
October 30th, 2020
Enalare Therapeutics Inc. announced today that it has appointed biopharma industry veteran Herm Cukier as its Executive Chairman of the Board, President, and Chief Executive Officer.